Mayo clinic launches lung disease biobank to unlock future treatments
NCT ID NCT03478826
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is creating a repository of blood samples from 635 people with interstitial lung diseases (ILD), pneumonia, and healthy volunteers. Researchers hope these samples will help identify biomarkers to improve diagnosis and treatment. No experimental treatments are given; participants simply donate blood for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this repository could help researchers discover biomarkers that guide treatment for interstitial lung diseases.
- What could go wrong
- This is an observational study that does not test any treatment. It only collects samples for future research, so there is no direct benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- Can AI catch lung scarring that doctors might miss?
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a smart oxygen device shorten hospital stays for pneumonia?
- Could everyday supplements shield your lungs?